Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Human stromal (mesenchymal) stem cells: basic biology and current clinical use for tissue regeneration.

Aldahmash A., Zaher W., Al-Nbaheen M., Kassem M.

Clinical Trial on Cardiovascular Disease, Chronic Wound, published in Ann Saudi Med (2012) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Ann Saudi Med (2012)
Country
Saudi Arabia
Reported sample size
—
Source database
PubMed
PMID
22156642
PMCID
PMC6087654
DOI
10.5144/0256-4947.2012.68
Citations
49

Abstract (original English)

Human stromal (mesenchymal) stem cells (hMSC) represent a group of non-hematopoietic stem cells present in the bone marrow stroma and the stroma of other organs including subcutaneous adipose tissue, placenta, and muscles. They exhibit the characteristics of somatic stem cells of self-renewal and multi-lineage differentiation into mesoderm-type of cells, e.g., to osteoblasts, adipocytes, chondrocytes and possibly other cell types including hepatocytes and astrocytes. Due to their ease of culture and multipotentiality, hMSC are increasingly employed as a source for cells suitable for a number of clinical applications, e.g., non-healing bone fractures and defects and also non-skeletal degenerative diseases like heart failure. Currently, the numbers of clinical trials that employ MSC are increasing. However, several biological and biotechnological challenges need to be overcome to benefit from the full potential of hMSC. In this current review, we present some of the most important and recent advances in understanding of the biology of hMSC and their current and potential use in therapy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Clinical Trials as TopicHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsRegeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research